FML FORTE SUMMARY
FML FORTE®
(fluorometholone ophthalmic suspension, USP) 0.25%
FML FORTE® sterile ophthalmic suspension is a topical anti-inflammatory product for ophthalmic use. Chemical Name: Fluorometholone: 9-Fluoro-11β, 17-dihydroxy-6α-methylpregna-1,4-diene-3,20-dione.
FML FORTE® suspension is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
|
NEWS HIGHLIGHTS
Published Studies Related to FML Forte (Fluorometholone Ophthalmic)
Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema
after cataract surgery. [2011]
DESIGN: Randomized double-masked single-center clinical trial... CONCLUSION: Nepafenac was more effective than fluorometholone in preventing
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2009.08]
PURPOSE: We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)... CONCLUSIONS: In patients with SAC, olopatadine, ketotifen, epinastine and emedastine are more efficacious than fluorometholone acetate in preventing itching and redness. All the antiallergic agents gave similar results in terms of reducing tearing, chemosis and eyelid swelling. Our data showed that impression cytology parameters improved after treatment with antiallergic agents in patients with SAC.
Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis. [2009.06]
AIMS: Bromfenac sodium (BF) 0.1% was compared with fluorometholone (FML) 0.02% for the treatment of seasonal allergic conjunctivitis when concomitantly used with disodium cromoglycate (DSCG) 2.0%... CONCLUSIONS: Bromfenac sodium for allergic conjunctivitis was effective, with efficacy equivalent to that of FML when used with DSCG.
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2008.07.08]
Purpose: We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)... Our data showed that impression cytology parameters improved after treatment with antiallergic agents in patients with SAC.
Comparison of tacrolimus, fluorometholone, and saline in mild-to-moderate contact
lens-induced papillary conjunctivitis. [2012]
contact lens-induced papillary conjunctivitis (CLPC)... CONCLUSIONS: Tacrolimus 0.05% may be a safe and effective treatment for mild to
Clinical Trials Related to FML Forte (Fluorometholone Ophthalmic)
Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel [Recruiting]
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas [Recruiting]
To evaluate the efficacy of ultraviolet-A (UVA)-induced cross-linking of corneal collagen
(CXL) as a method to increase the biomechanical and biochemical stability of the cornea by
inducing additional cross-links within or between collagen fibers using UVA light and the
photo- mediator riboflavin. The purpose of this study is to generate data for presentation
at medical meetings and for peer-review publication
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas [Recruiting]
The purpose of this study is to evaluate the efficacy of ultraviolet-A (UVA)-induced
cross-linking of corneal collagen (CXL) as a method to increase the biomechanical and
biochemical stability of the cornea by inducing additional cross-links within or between
collagen fibers using UVA light and the photo- mediator riboflavin. The purpose of this
study is to generate data for presentation at medical meetings and for peer-review
publication. The data generated by this study will not be submitted to the FDA to support
commercialization of these riboflavin drops.
Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy. [Recruiting]
The purpose of this study is to evaluate the potential of [18F]-ML-10 to serve as an imaging
tool for the early detection of response of brain metastases to radiation therapy. Such
early detection may help early identification of responsive and non-responsive lesions. The
experimental design of the present study aims to evaluate the potential of PET imaging with
[18F]-ML-10 to address the currently unmet clinical need for very early (within one
day)assessment of response to therapy. Currently, response assessment is available only
after several weeks or months after completion of therapy, when tumor shrinkage can be
detected by anatomical imaging (by MRI). Early detection of tumor response to treatment is
now widely-recognized as a highly-desirable goal in oncology, and is respectively the target
of intense research worldwide. In the future, the option to know early upon treatment
administration, that the treated tumor is a non-responsive, may improve clinical management
of patients with brain metastases of solid tumors.
Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK) [Recruiting]
The purpose of this study is to compare two different commonly used steroid dosing regimens
after Descemet's membrane endothelial keratoplasty (DMEK) transplant surgery. The
investigators hope to determine if one is more effective at preventing rejection or if both
are equally effective.
|
